We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
25
Jun 2026
A study published recently in Current Molecular Pharmacology has uncovered a key mechanism linking aging to persistent pulmonary fibrosis, identifying the transcriptional regulator fPRDM16 as a potential therapeutic target.
25
Jun 2026
A comprehensive review recently published in Current Molecular Pharmacology consolidates the growing evidence surrounding the Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) as a central amplifier of innate immune responses and a promising therapeutic target for a range of inflammatory diseases.
25
Jun 2026
Taking a supplement before a hepatectomy, a surgery in which part of the liver is removed, may help the organ recover more quickly and become more resistant to further damage.
25
Jun 2026
Leading CAR T cell therapy researchers have developed a human-in-the-loop artificial intelligence (AI) framework that firmly centers scientists' expertise to find viable target antigens for CAR T cell therapy.